

Dan S Gombos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8554176/publications.pdf>

Version: 2024-02-01

71
papers

1,929
citations

279798

23
h-index

265206

42
g-index

78
all docs

78
docs citations

78
times ranked

2443
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100514.	1.7	5
2	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016). <i>Frontiers in Oncology</i> , 2022, 12, 853076.	2.8	2
3	Partial spontaneous regression of choroidal melanoma: A case image with histopathology and gene expression profiling. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101517.	0.7	0
4	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	1.6	156
5	Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 6-15.	1.4	12
6	Response criteria for intraocular retinoblastoma: RBâ€¦RECIST. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28964.	1.5	6
7	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	3.7	5
8	Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. <i>Cancers</i> , 2021, 13, 3292.	3.7	4
9	Immune-Related Oral, Otologic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 399-416.	1.6	2
10	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
11	A singleâ€¦arm study of systemic and subâ€¦tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28502.	1.5	7
12	Head and neck surgical oncology in the time of a pandemic: Subsiteâ€¦specific triage guidelines during the <sc>COVID</sc>â€¦19 pandemic. <i>Head and Neck</i> , 2020, 42, 1194-1201.	2.0	38
13	Immune-Related Oral, Otologic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 295-307.	1.6	10
14	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 856.	3.7	31
15	Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. <i>Journal of NeuroInterventional Surgery</i> , 2019, 11, 1273-1276.	3.3	14
16	Screening Children at Risk for Retinoblastoma. , 2019, , 271-274.		0
17	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	3.7	27
18	DICER1 Syndrome. <i>Ophthalmology</i> , 2019, 126, 296-304.	5.2	20

#	ARTICLE	IF	CITATIONS
19	Screening Children at Risk for Retinoblastoma. <i>Ophthalmology</i> , 2018, 125, 453-458.	5.2	92
20	Metastatic Melanoma of the Optic Nerve Sheath. <i>Neuro-Ophthalmology</i> , 2018, 42, 187-190.	1.0	4
21	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1351-1359.	10.7	63
22	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
23	Reply. <i>Ophthalmology</i> , 2018, 125, e64-e65.	5.2	0
24	Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 1441-1441.	1.4	5
25	Vitreous Seeds in Retinoblastoma. <i>Ophthalmology</i> , 2017, 124, 1540-1547.	5.2	31
26	Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26394.	1.5	18
27	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncotarget</i> , 2017, 6, e1321187.	4.6	45
28	Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. <i>Oncotarget</i> , 2017, 8, 58709-58727.	1.8	37
29	Late Presentation of Retinoblastoma in a Teen with Aicardi Syndrome. <i>Ocular Oncology and Pathology</i> , 2016, 2, 181-184.	1.0	4
30	Uveal melanoma: From diagnosis to treatment and the science in between. <i>Cancer</i> , 2016, 122, 2299-2312.	4.1	272
31	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2612-2618.	1.3	1
32	Survival Outcomes of Primary Intraocular Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 109-113.	1.3	30
33	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 575-581.	1.2	24
34	Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1531-1538.	2.5	18
35	Diagnostic Ophthalmic Ultrasound for Radiologists. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 327-365.	1.0	29
36	Children's Oncology Group (COG) Trials for Retinoblastoma. , 2015, , 215-223.		3

#	ARTICLE	IF	CITATIONS
37	A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. <i>Practical Radiation Oncology</i> , 2015, 5, e169-e176.	2.1	40
38	Conjunctival Melanoma—Clinical Pearls Now, Hope for the Future. <i>JAMA Ophthalmology</i> , 2015, 133, 1303.	2.5	1
39	Sinonasal melanoma arising from conjunctival primary acquired melanosis. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208522-bcr2014208522.	0.5	3
40	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. <i>Practical Radiation Oncology</i> , 2014, 4, e189-e194.	2.1	22
41	Principles of Cryotherapy. , 2014, , 77-82.		0
42	Retinoblastoma and the RB1 Cancer Syndrome. , 2013, , 1-27.		0
43	Surveillance Options for Patients with Uveal Melanoma Following Definitive Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 382-387.	3.8	15
44	Surveillance Options for Patients with Uveal Melanoma Following Definitive Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 382-387.	3.8	16
45	Management of Radiation-Induced Severe Anophthalmic Socket Contracture in Patients With Uveal Melanoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2012, 28, 208-212.	0.8	18
46	Leuprolide Monotherapy for Choroidal Metastasis From Prostate Adenocarcinoma. <i>JAMA Ophthalmology</i> , 2012, 130, 1225.	2.4	2
47	Residual Intraretinal Retinoblastoma After Chemoreduction Failure. <i>JAMA Ophthalmology</i> , 2012, 130, 246.	2.4	7
48	Re. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2012, 28, 235-237.	0.8	0
49	Retinoblastoma in the perinatal and neonatal child. <i>Seminars in Fetal and Neonatal Medicine</i> , 2012, 17, 239-242.	2.3	22
50	Retinoblastoma: An Overview. <i>Indian Journal of Pediatrics</i> , 2012, 79, 916-921.	0.8	20
51	Intra-arterial Chemotherapy for Advanced Retinoblastoma. <i>JAMA Ophthalmology</i> , 2011, 129, 1487.	2.4	29
52	GPNMB expression in uveal melanoma: a potential for targeted therapy. <i>Melanoma Research</i> , 2010, 20, 184-190.	1.2	43
53	THE ASSOCIATION OF CUTANEOUS AND IRIS NEVI WITH UVEAL MELANOMA: A META-ANALYSIS. <i>Evidence-Based Ophthalmology</i> , 2010, 11, 90-91.	0.0	1
54	Multidisciplinary Management of Retinoblastoma: Diagnosis, Treatment, and Future Direction. , 2010, , 179-199.		2

#	ARTICLE	IF	CITATIONS
55	Choroidal and Conjunctival Metastases From Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 448-449.	1.3	10
56	Ischemic Optic Neuropathy Associated With Low-Dose Interferon Alfa: Report of Two Cases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 86-87.	1.3	6
57	A Novel Von Hippel-Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. Cancer Investigation, 2008, 26, 642-646.	1.3	2
58	Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy. Physics in Medicine and Biology, 2008, 53, 1581-1594.	3.0	44
59	Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy. Physics in Medicine and Biology, 2007, 52, 3979-3990.	3.0	67
60	Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Ophthalmology, 2007, 114, 1378-1383.	5.2	201
61	Principles of cryotherapy. , 2007, , 34-36.		1
62	Current treatment and management of retinoblastoma. Current Oncology Reports, 2007, 9, 453-458.	4.0	22
63	Retinoblastoma and Hypochondroplasia: A Case Report of Two Germline Mutations Arising Simultaneously. Ophthalmic Genetics, 2005, 26, 107-110.	1.2	2
64	Estimating the incidence of retinoblastoma in Texas. Texas Medicine, 2005, 101, 70-2.	0.0	4
65	Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology, 2004, 111, 2254-2258.	5.2	30
66	Orbital and Optic Chiasmal Extension of Uveal Melanoma. Ophthalmic Plastic and Reconstructive Surgery, 2004, 20, 387-390.	0.8	4
67	Current Management of Retinoblastoma. Retina, 2004, 24, 825-827.	1.7	4
68	Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. British Journal of Ophthalmology, 2002, 86, 80-83.	3.9	97
69	Cholesterosis Following Chemoreduction for Advanced Retinoblastoma. JAMA Ophthalmology, 2000, 118, 440.	2.4	11
70	Familial retinoblastoma, where and when?. Acta Ophthalmologica, 1998, 76, 334-338.	0.3	37
71	THE TOPOGRAPHY OF BILATERAL RETINOBLASTOMA LESIONS. Retina, 1996, 16, 232-239.	1.7	46